Drew Endy

Drew Endy

  • Martin Family University Fellow in Undergraduate Education
  • Faculty Co-Director of Degree Programs, Hasso Plattner Institute of Design
  • Faculty of Bioengineering, Stanford University
  • Core Faculty, Center for International Security and Cooperation

Biography

Drew Endy is a bioengineer at Stanford University who studies and teaches synthetic biology. His goals are civilization-scale flourishing and a renewal of liberal democracy. Prof. Endy helped launch new undergraduate majors in bioengineering at both MIT and Stanford and also the iGEM — a global genetic-engineering “Olympics” enabling thousands of students annually. His past students lead companies like Ginkgo Bioworks and Octant. He is married to Christina Smolke CEO of Antheia the essential medicine company. Endy served on the US National Science Advisory Board for Biosecurity (NSABB) the Committee on Science Technology & Law (CSTL) the International Union for the Conservation of Nature’s (IUCN) Synthetic Biology Task Force and, briefly, the Pentagon’s Defense Innovation Board (DIB). He currently serves on the World Health Organization’s (WHO) Advisory Committee on Variola Virus Research. Esquire magazine recognized Drew as one of the 75 most influential people of the 21st century.

In The News

The White House in Washington D.C.
Q&As

At White House Summit on Bioeconomy, Work of Stanford Scholars Takes Major Leap Forward

With more funding and resources being allocated to America's biotech sector, CISAC affiliate Megan Palmer and core faculty member Drew Endy describe the opportunities and challenges of developing a more robust, ethical, and equitable bioeconomy.
cover link At White House Summit on Bioeconomy, Work of Stanford Scholars Takes Major Leap Forward
Drew Endy Lab
Q&As

A View from the CT Foxhole: Drew Endy, Associate Chair, Bioengineering, Stanford University

Drew Endy argues the United States urgently needs a bio strategy to take advantage of rapid advances in biotechnology, protect against the growing danger posed by its potential malevolent use, and prevent the United States from permanently falling behind as a biopower.
cover link A View from the CT Foxhole: Drew Endy, Associate Chair, Bioengineering, Stanford University